INTERIM REPORT Q1, 1 JANUARY -
Significant events during the Quarter
- Successful outcomes of LaminarPace™ Feasibility study with Biotech partner
On
The assessment concluded that the resulting dry powder material demonstrated excellent mRNA activity when reconstituted and tested in in-vitro cell studies. The assessment also concluded that the LaminarPace™ treatment resulted in well-preserved mRNA content in LNP particles with adequate encapsulation efficiency. Furthermore, the treatment resulted in well-preserved lipid nanoparticles with good particle size and preserved size distribution.
- Financing secured through directed share issue and rights issue
On
The Directed New Share Issue is part of a long-term financing arrangement with GCF under which
The Board of Directors of
Considering the Directed New Share Issue, and provided that the Rights Issue is fully subscribed,
* Volume-Weighted Average Price, VWAP, is calculated by totalling the SEK traded for every transaction (price multiplied by the volume) and then dividing by the total shares traded.
Ziccum has proven excellent mRNA activity in animal study with LaminarPace™ material
On
- Ziccums CEO
Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family Office
On
Ziccum announces outcome in rights issue
On
Ziccum reports significant progress in 3D-modelling project with model completion
On
Ziccum inhalable mRNA/LNP project confirms excellent properties obtained by LaminarPace™
On
Significant events after the Quarter
Ziccum strengthens and streamlines business and finance functions
On
Ziccum CEO to present at first annual event for Biopharma/Biotech Disruptors hosted by major US bank inNew York City
On
Ziccum contracts RFR Solutions for GMP manufacturing in next phase of technology scale-out
On
CEO statement
A quarter of intense partner interaction and significant mRNA/LNP milestones - beyond our expectations
The first quarter 2024 brought very important milestones, strongly confirming our mRNA capabilities including both excellent readouts from our partnered feasibility study and generating the first ever animal data for LaminarPace™-treated pharmaceuticals with perfect results. The results are surpassing our expectations of securing good proof for the LaminarPace™ performance for RNA materials, the most sought-after target, currently revolutionizing pharmaceutical and vaccine development world-wide!
Another important step completed was securing financing, where the rights issue, welcoming all existing owners to join, combined with adding a strong US investor in a directed issue on equal terms provided a sound setting for the company ahead. We are proud of the successful model, limited resulting dilution and good outcome in the current difficult market conditions. The quarter also brought significant revenue, thanks to our paid feasibility programs.
Proving LaminarPace™ for mRNA/LNP – the highest value segment with booming development in industry
Within the field of biopharmaceuticals, the most in-demand but also most demanding modality to turn into robust form, is the highly delicate mRNA in lipid nanoparticle formulation (mRNA/LNP). We are now proceeding from the stage of the exciting potential of treating mRNA, with initial studies during 2023, to the stage of solid datasets successfully proving mRNA/LNP treatments, including repeated external validations from reputable industry players – and including the all-important big step of animal data proof.
The animal study, so called in-vivo, reported end January could prove the preservation of full mRNA activity after LaminarPace™-drying. It is fantastic to get this result with such clarity in the first model chosen for in-vivo studies. Thanks to this we can proceed without repeated trials of the activity parameter in-vivo and move on to more specific parameters such as immunological responses. Furthermore, the internal mRNA/LNP trial runs have repeatedly delivered very high mRNA activity in-vitro for various lipid compositions – something we presented at the mRNA
It is rewarding to so rapidly have reached critical results confirming how LaminarPace™ can enable new, better, more cost-efficient, and far more sustainable RNA treatments – and to see the industry demand for this come into focus.
Taking our Partnered Feasibility studies forward
In January we could communicate a very good Biotech partner readout, where all mRNA/LNP data were meeting the targets and the mRNA activity preservation was deemed excellent, by partner validation. Again, these results are exceeding our expectations, in our first partnered study for mRNA. For our Big Pharma partner, the mRNA project pilot runs were concluded with good results during the quarter and the project now continues with joint assessments.
Patience is now needed to see the development in these partnerships. Pharmaceutical development is always a lengthy process – even if the RNA platform opens up for quicker progress – and the decision processes within large organizations in pharmaceutical industry consist of many committee reviews. Like defined in our business plan, we strive to continuously build a pipeline of additional dialogues, as we have the great benefit of a platform that can be applied with many partners.
We also have reached a highly rewarding Market milestone during this quarter, with several large corporations now contacting us directly, as
The
The quarter brought significant work for IP protection, where we are supporting the existing three patent applications with the important and solid data packages generated internally. We are also taking great strides in analytical development, quality assurance and planning for regulatory fulfilment – all to ensure GMP readiness - thanks to our organization being nicely strengthened in these areas during 2023.
We continue to carefully build our high caliber
All in all, what a productive quarter! My gratitude to everyone involved for great efforts, my warm welcome to our new investors and keen appreciation to everyone for continued, important support.
Financial highlights
January - March in brief
- Operating income: kSEK 3,248 (638).
- Result for the quarter: kSEK -3,958 (-4,872).
- Earnings per share:
SEK -0.26 (-0.35). - Cash flow for the quarter: kSEK 6,065 (-3,928).
- Cash at the end of the reporting period: kSEK 9,059 (19,023).
Financial Summary
Q1 | Q1 | Jan-Dec | ||
kSEK | 2024 | 2023 | 2023 | |
Operating income | 3,248 | -638 | 6,318 | |
Operating result | -4,022 | -4,936 | -21,560 | |
Result | -3,958 | -4,872 | -21,412 | |
Balance sheet total | 20,307 | 28,915 | 14,972 | |
Cash flow | 6,065 | -3,928 | -19,957 | |
Cash and cash equivalents | 9,059 | 19,023 | 2,994 | |
Equity ratio % | 65 | 85 | 57 | |
Per share data (SEK) | ||||
Number of shares | 15,372,258 | 13,806,142 | 13,806,142 | |
Result per share before and after dilution* | -0.26 | -0.35 | -1.55 | |
Cash flow per share | 0,39 | -0.28 | -1.45 | |
Equity per share | 0.85 | 1.78 | 0.62 |
* Dilution effects is not calculated when the result is negative
© Modular Finance, source